| dc.contributor | Molina Castaño, Carlos Federico | |
| dc.creator | Guzmán Prado, Yuli | |
| dc.creator | Sierra Arango, Fernando | |
| dc.creator | Kattah Calderon, William | |
| dc.date.accessioned | 2016-10-12T18:36:06Z | |
| dc.date.available | 2016-10-12T18:36:06Z | |
| dc.date.created | 2016-10-12T18:36:06Z | |
| dc.date.issued | 2016 | |
| dc.identifier | http://repository.urosario.edu.co/handle/10336/12402 | |
| dc.description.abstract | Several studies claim that gastric acid has an important role on levothyroxine (LT4) absorption with controversial findings about proton-pump inhibitors (PPI) and LT4 interaction. The aim of this study was to evaluate the effect of concomitant use of PPI and LT4 on TSH level in adult patients with primary hypothyroidism.
A systematic review was conducted using databases including: Medline, Embase, Lilacs, Bireme, Scielo, Cochrane and University of York, Access Pharmacy, Google Scholar, Dialnet and Opengray. Summaries of intervention effects were provided by calculating TSH mean differences, 95% confidence intervals and two sided p values. Heterogeneity between the studies on effect measures was assessed using both the χ2 test and the I2 statistic. Additional subgroup analyses by age and sensitivity analyses were carried out. Review Manager program endorsed by the Cochrane Collaboration was used.
We identified 5 elegible studies for qualitative analysis and 3 for meta-analysis. The mean difference obtained was 0.21 mIU/L (95% CI: 0.02 to 0.40, p = 0.03; I2: 0%). In the subgroup analysis (over 55 years) the mean difference was 0.21 mIU/L (95% CI: 0.01 to 0.40, p = 0.27; I2: 19%). In the sensitivity analysis the study with larger sample was excluded and the mean difference was 0.49 mIU/L (95% CI -0.12 to 1.11, p = 0.12; I2: 0%).
The difference on TSH value after LT4 and PPI consumption does not represent a clinically significant difference. However, it is necessary to carry out randomized controlled trials and to evaluate the effect on free T4 level. | |
| dc.language | spa | |
| dc.publisher | Universidad del Rosario | |
| dc.publisher | Maestría en Epidemiología | |
| dc.publisher | Facultad de medicina | |
| dc.rights | info:eu-repo/semantics/embargoedAccess | |
| dc.rights | Restringido (Temporalmente bloqueado) | |
| dc.rights | EL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma.
PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe.
EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización.
--------------------------------------
POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos. | |
| dc.source | instname:Universidad del Rosario | |
| dc.source | reponame:Repositorio Institucional EdocUR | |
| dc.source | 1. Chakera AJ, Pearce SH, Vaidya B. Treatment for primary hypothyroidism: current approaches and future possibilities. Drug Design, Development and Therapy. 2012;6:1-11. | |
| dc.source | 2. Arroyo J, Gil P, Llauradó G, Caixàs A. Primary hypothyroidism: Considerations for a rational use of levothyroxine therapy. Med Clin (Barc). 2011;136:207-14. | |
| dc.source | 3. Khandelwal D, Tandon N. Overt and subclinical hypothyroidism: who to treat and how. Drugs. 2012;72:17-33. | |
| dc.source | 4. Badillo R, Francis D. Diagnosis and treatment of gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther. 2014;5:105-12. | |
| dc.source | 5. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308-328. | |
| dc.source | 6. Hom C, Vaezi MF. Extra-esophageal manifestations of gastroesophageal reflux disease: diagnosis and treatment. Drugs. 2013;73:1281-1295. | |
| dc.source | 7. Yang JH, Kang HS, Lee SY, Kim JH, Sung IK, Park HS, Shim CS, Jin CJ. Recurrence of gastroesophageal reflux disease correlated with a short dinner-to-bedtime interval. J Gastroenterol Hepatol. 2014;29:730-735. | |
| dc.source | 8. Jobe BA, Richter JE, Hoppo T, Peters JH, Bell R, Dengler WC, DeVault K, Fass R, Gyawali CP, Kahrilas PJ, et al. Preoperative diagnostic workup before antireflux surgery: an evidence and experience-based consensus of the Esophageal Diagnostic Advisory Panel. J Am Coll Surg. 2013;217:586-597. | |
| dc.source | 9. Rickenbacher N, Kötter T, Kochen MM, Scherer M, Blozik E. Fundoplication versus medical management of gastroesophageal reflux disease: systematic review and meta-analysis. Surg Endosc. 2014;28:143-155. | |
| dc.source | 10. Pallati PK, Shaligram A, Shostrom VK, Oleynikov D, McBride CL, Goede MR. Improvement in gastroesophageal reflux disease symptoms after various bariatric procedures: Review of the Bariatric Outcomes Longitudinal Database. Surg Obes Relat Dis. 2014;10:502-507. | |
| dc.source | 11. Dorval E, Rey JF, Soufflet C, Halling K, Barthelemy P. Perspectives on gastroesophageal reflux disease in primary care: the REFLEX study of patient–physician agreement. BMC Gastroenterol. 2011;11-25. | |
| dc.source | 12. Ward LS. The difficult patient: drug interaction and the influence of concomitant diseases on the treatment of hypothyroidism. Arq Bras Endocrinol Metabol. 2010;54:435-42. | |
| dc.source | 13. Groener JB, Lehnhoff D, Piel D, et al. Subcutaneous application of levothyroxine as successful treatment option in a patient with malabsorption. Am J Case Rep. 2013;14:48-51. | |
| dc.source | 14. Gaitonde DY, Rowley KD, Sweeney LB. Hypothyroidism: an update. Am Fam Physician. 2012;86:244-51. | |
| dc.source | 15. Shin JM, Kim N. Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors. J Neurogastroenterol Motil 2013;19:25-35. | |
| dc.source | 16. Benvenga S. When thyroid hormone replacement is ineffective? Curr Opin Endocrinol Diabetes Obes. 2013;20:467-77. | |
| dc.source | 17. Walker JN, Shillo P, Ibbotson V, et al. A thyroxine absorption test followed by weekly thyroxine administration: a method to assess non-adherence to treatment. Eur J Endocrinol. 2013;168:913-7. | |
| dc.source | 18. Garber JR, Cobin RH, Gharib H, et al. Clinical practice guide- lines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18:988-1028. | |
| dc.source | 19. Donangelo I, Braunstein GD. Update on subclinical hyperthyroidism. Am Fam Physician. 2011;83:933-938. | |
| dc.source | 20. Linn WD, Wofford MR, O'Keefe ME, Posey LM. Pharmacotherapy in Primary Care. McGraw-Hill Education; 2009. | |
| dc.source | 21. Kasper D., Fauci A., Hauser S., Longo D., Jameson JL, Loscalzo J. Harrison's Principles of Internal Medicine, 19 ed. McGraw-Hill; 2015. | |
| dc.source | 22. Brunton L, Chabner B, Knollmann B. Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 12e. The McGraw-Hill; 2011. | |
| dc.source | 23. DiPiro J, Talbert R, Yee G, Matzke G, Wells B, Posey LM. Pharmacotherapy: A Pathophysiologic Approach, 9e. McGraw-Hill Education; 2014. | |
| dc.source | 24. Khandelwal D, Tandon N. Overt and subclinical hypothyroidism: who to treat and how. Drugs. 2012;72(1):17-33. | |
| dc.source | 25. Damle N, Bal C, Soundararajan R, et al. A curious case of refractory hypothyroidism due to selective malabsorption of oral thyroxine. Indian J Endocrinol Metab. 2012;16(3):466-68. | |
| dc.source | 26. Cappelli C, Pirola I, Gandossi E, Formenti A, Castellano M. Oral liquid levothyroxine treatment at breakfast: a mistake? Eur J En- docrinol. 2014;170:95-99. | |
| dc.source | 27. Saraceno G, Vita R, Trimarchi F, Benvega S. A liquid formulation of L-thyroxine (L-T4) solves problems of incomplete normalization/suppression of serum TSH caused by proton pump inhibitors (PPI) on conventional tablet formulations of L-T4. Endocrine Abstracts. 2012;29:1626. | |
| dc.source | 28. Centanni M. Thyroxine treatment: absorption, malabsorption, and novel therapeutic approaches. Endocrine. 2013;43:8-9. | |
| dc.source | 29. Dietrich JW, Gieselbrecht J, Holl RW, Boehm BO. Absorption Kinetics of Levothyroxine Is Not Altered by Proton-pump Inhibitor Therapy. Horm Metab Res. 2006;38(1):57-59. | |
| dc.source | 30. Abib Rde C, Vaisman M. Is it necessary to increase the dose of levothyroxine in patients with hypothyroidism who use omeprazole?. Arq Bras Endocrinol Metabol. 2014;58(7):731-736. | |
| dc.source | 31. Sachmechi I, Reich DM, Aninyei M, Wibowo F, Gupta G, Kim PJ.
Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract. 2007;13:345-349. | |
| dc.source | 32. Vita G, Saraceno F, Trimarchi S, Benvenga S. Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors. J. Clin. Endocrinol. Metab. 2014;99: 4481-4486. | |
| dc.source | 33. Irving S, Vadiveloo T, Leese GP. Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS). Clin Endocrinol. 2015;82:136-141. | |
| dc.subject | Hipotiroidismo | |
| dc.subject | Absorción | |
| dc.subject | Ulcera péptica | |
| dc.subject | Dispepsia | |
| dc.subject | Reflujo gastroesofágico | |
| dc.title | Efecto del consumo concomitante de inhibidores de bomba protones y levotiroxina : revisión sistemática y metaanálisis | |
| dc.type | masterThesis | |
